All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for MERCK & CO. INC. · Manufacturer of pharmaceuticals

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 17, 2025

Official filing document

Bills named in this filing 4

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 4

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R.1, One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes.

Trade (domestic/foreign)

Issues related to tariffs.

Health Issues

Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.